Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
Metrics: PDF 3131 views | HTML 4479 views | ?
1Department of Microbiology & Immunology Brody School of Medicine at East Carolina University Greenville, NC 27858 USA
2These two authors contributed equally to the studies.
3Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore Università di Bologna, Bologna, Italy
4 IGM-CNR, Sezione di Bologna, C/o IOR, Bologna, Italy
5Department of Biomedical Sciences University of Catania, Catania, Italy
6Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine
Received: June 23, 2011; Accepted: July 1, 2011; Published: July 1, 2011;
Keywords: Akt, mTOR, Targeted Therapy, Drug Resistance
James A. McCubrey, email:
Elucidating the response of breast cancer cells to chemotherapeutic and hormonal based drugs is clearly important as these are frequently used therapeutic approaches. A signaling pathway often involved in chemo- and hormonal-resistance is the Ras/PI3K/PTEN/Akt/mTOR cascades. In the studies presented in this report, we have examined the effects of constitutive activation of Akt on the sensitivity of MCF-7 breast cancer cells to chemotherapeutic- and hormonal-based drugs as well as mTOR inhibitors. MCF-7 cells which expressed a constitutively-activated Akt-1 gene [∆Akt-1(CA)] were more resistant to doxorubicin, etoposide and 4-OH-tamoxifen (4HT) than cells lacking ∆Akt-1(CA). Cells which expressed ∆Akt-1(CA) were hypersensitive to the mTOR inhibitor rapamycin. Furthermore, rapamycin lowered the IC50s for doxorubicin, etoposide and 4HT in the cells which expressed ∆Akt-1(CA), demonstrating a potential improved method for treating certain breast cancers which have deregulated PI3K/PTEN/Akt/mTOR signaling. Understanding how breast cancers respond to chemo- and hormonal-based therapies and the mechanisms by which they can become drug resistant may enhance our ability to treat breast cancer. These results also document the potential importance of knowledge of the mutations present in certain cancers which may permit more effective therapies.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.